mirna在高级别胶质瘤中的诊断和预后价值：一项系统综述。

Q2 Pharmacology, Toxicology and Pharmaceutics

F1000Research Pub Date : 2025-01-15 eCollection Date: 2024-01-01 DOI:10.12688/f1000research.151350.2

Renindra Ananda Aman, Mohammad Galih Pratama, Ricky Rusydi Satriawan, Irfani Ryan Ardiansyah, I Ketut Agus Suanjaya

{"title":"mirna在高级别胶质瘤中的诊断和预后价值：一项系统综述。","authors":"Renindra Ananda Aman, Mohammad Galih Pratama, Ricky Rusydi Satriawan, Irfani Ryan Ardiansyah, I Ketut Agus Suanjaya","doi":"10.12688/f1000research.151350.2","DOIUrl":null,"url":null,"abstract":"Background: Gliomas, particularly glioblastomas, have grim prognoses, necessitating early diagnostic and prognostic indicators. MicroRNAs (miRNAs), influential in cancer research, show potential as glioma biomarkers. This systematic review aimed to examine the efficacy of miRNAs in the diagnosis and prognosis of high-grade glioma.Methods: A comprehensive search was conducted of PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from 2013 to 2023. The eligibility criteria included high-grade glioma, histopathological confirmation, miRNA samples from cerebrospinal fluid or plasma, and relevant outcome data. Studies were excluded if they were experimental or reviews and not in English.Results: Of the 1120 initial results, 8 studies involving 660 subjects met the inclusion criteria. Several studies have assessed miRNA expression and its association with diagnosis and prognosis of high-grade gliomas. Overexpression of miR-221, miR-222, miR-210, miR-21, miR-125b, and miR-223 and under-expression of miR-15b and miR-124-3p showed significant potential in differentiating high-grade glioma patients from controls. Additionally, miRNAs are associated with distinct tumorigenic pathways.Conclusion: Elevated or depressed expression levels of specific circulating miRNAs hold significant promise as noninvasive biomarkers for the diagnosis and prognosis of high-grade glioma. These miRNAs offer valuable insights into disease progression and patient outcome. Further validation through extensive clinical trials and in-depth mechanistic studies is essential to realize their full clinical utility.","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"13 ","pages":"796"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826073/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnostic and Prognostic Values of miRNAs in High-Grade Gliomas: A Systematic Review.\",\"authors\":\"Renindra Ananda Aman, Mohammad Galih Pratama, Ricky Rusydi Satriawan, Irfani Ryan Ardiansyah, I Ketut Agus Suanjaya\",\"doi\":\"10.12688/f1000research.151350.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Gliomas, particularly glioblastomas, have grim prognoses, necessitating early diagnostic and prognostic indicators. MicroRNAs (miRNAs), influential in cancer research, show potential as glioma biomarkers. This systematic review aimed to examine the efficacy of miRNAs in the diagnosis and prognosis of high-grade glioma.Methods: A comprehensive search was conducted of PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from 2013 to 2023. The eligibility criteria included high-grade glioma, histopathological confirmation, miRNA samples from cerebrospinal fluid or plasma, and relevant outcome data. Studies were excluded if they were experimental or reviews and not in English.Results: Of the 1120 initial results, 8 studies involving 660 subjects met the inclusion criteria. Several studies have assessed miRNA expression and its association with diagnosis and prognosis of high-grade gliomas. Overexpression of miR-221, miR-222, miR-210, miR-21, miR-125b, and miR-223 and under-expression of miR-15b and miR-124-3p showed significant potential in differentiating high-grade glioma patients from controls. Additionally, miRNAs are associated with distinct tumorigenic pathways.Conclusion: Elevated or depressed expression levels of specific circulating miRNAs hold significant promise as noninvasive biomarkers for the diagnosis and prognosis of high-grade glioma. These miRNAs offer valuable insights into disease progression and patient outcome. Further validation through extensive clinical trials and in-depth mechanistic studies is essential to realize their full clinical utility.\",\"PeriodicalId\":12260,\"journal\":{\"name\":\"F1000Research\",\"volume\":\"13 \",\"pages\":\"796\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826073/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/f1000research.151350.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.151350.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

背景：胶质瘤，特别是胶质母细胞瘤预后恶劣，需要早期诊断和预后指标。MicroRNAs （miRNAs）在癌症研究中具有重要影响，显示出作为胶质瘤生物标志物的潜力。本系统综述旨在探讨mirna在高级别胶质瘤的诊断和预后中的作用。方法：综合检索PubMed、EMBASE、Cochrane Library和Web of Science 2013 - 2023年发表的研究。入选标准包括高级别胶质瘤、组织病理学证实、脑脊液或血浆miRNA样本以及相关结局数据。非英文的实验性或综述性研究被排除在外。结果：在1120个初步结果中，8项研究660名受试者符合纳入标准。一些研究已经评估了miRNA表达及其与高级别胶质瘤的诊断和预后的关系。miR-221、miR-222、miR-210、miR-21、miR-125b和miR-223的过表达以及miR-15b和miR-124-3p的过表达在区分高级别胶质瘤患者和对照组中具有显著的潜力。此外，mirna与不同的致瘤途径相关。结论：特异性循环mirna表达水平的升高或降低作为高级别胶质瘤诊断和预后的非侵入性生物标志物具有重要的前景。这些mirna为疾病进展和患者预后提供了有价值的见解。通过广泛的临床试验和深入的机制研究进一步验证是实现其充分临床应用的必要条件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Diagnostic and Prognostic Values of miRNAs in High-Grade Gliomas: A Systematic Review.

Background: Gliomas, particularly glioblastomas, have grim prognoses, necessitating early diagnostic and prognostic indicators. MicroRNAs (miRNAs), influential in cancer research, show potential as glioma biomarkers. This systematic review aimed to examine the efficacy of miRNAs in the diagnosis and prognosis of high-grade glioma.

Methods: A comprehensive search was conducted of PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from 2013 to 2023. The eligibility criteria included high-grade glioma, histopathological confirmation, miRNA samples from cerebrospinal fluid or plasma, and relevant outcome data. Studies were excluded if they were experimental or reviews and not in English.

Results: Of the 1120 initial results, 8 studies involving 660 subjects met the inclusion criteria. Several studies have assessed miRNA expression and its association with diagnosis and prognosis of high-grade gliomas. Overexpression of miR-221, miR-222, miR-210, miR-21, miR-125b, and miR-223 and under-expression of miR-15b and miR-124-3p showed significant potential in differentiating high-grade glioma patients from controls. Additionally, miRNAs are associated with distinct tumorigenic pathways.

Conclusion: Elevated or depressed expression levels of specific circulating miRNAs hold significant promise as noninvasive biomarkers for the diagnosis and prognosis of high-grade glioma. These miRNAs offer valuable insights into disease progression and patient outcome. Further validation through extensive clinical trials and in-depth mechanistic studies is essential to realize their full clinical utility.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

5.00

自引率

0.00%

发文量

1646

审稿时长

1 weeks

期刊介绍： F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.